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The immune system mediates tissue responses under both phys-
iological and pathological conditions. In addition to leukocyte
subsets, non-hematopoietic tissue cell types actively contribute
to shaping tissue responses, including the inflammatory, fibro-
genic, and regenerative components. TWEAK and its receptor
Fn14, members of the TNF/TNFR superfamily, have emerged as a
prominent molecular axis regulating tissue responses (1). Gen-
erally leukocyte-derived, TWEAK signals through Fn14, which
is highly induced in injured and disease tissues on the surface
of parenchymal, vascular, stromal, and progenitor cells, thereby
orchestrating a host of tissue-shaping processes, including inflam-
mation, angiogenesis, cell proliferation, and death, and regula-
tion of progenitor cells. Of the downstream signaling pathways,
particular attention has been given to the non-canonical NFκB
pathway, given that TWEAK induces acute activation of canon-
ical NFκB but prolonged non-canonical NFκB activation. Thus,
non-canonical NFκB signaling may be a key mechanism under-
lying TWEAK/Fn14-induced tissue responses. The non-canonical
NFκB pathway is known to play a role in immunity and disease
pathologies and is typically activated by only a subset of TNFR
superfamily members, including Fn14, TNFR2, BAFFR, CD40,
LTβR, and RANK. Thus, there is also broad interest in the role of
this subset of TNFR superfamily members and their downstream
signaling potentials in the regulation of processes underlying tissue
remodeling in health and disease. This Research Topic is addressed
in a compilation of 19 expert reviews and 1 original research
article.
The TWEAK/Fn14 pathway as an injury-inducible mediator
of pleiotropic responses is introduced in a review of the work
implicating sustained Fn14 signaling in disease pathogenesis and
encompassing the current TWEAK/Fn14-targeting approaches for
treatment of human disease (2). Broad relevance to neurological
diseases is supported by a basic TWEAK/Fn14 role in regulating
the structure and function of the neurovascular unit, thereby reg-
ulating blood–brain barrier (BBB) permeability (3). Furthermore,
BBB damage appears to be an important component of neu-
ropsychiatric systemic lupus erythematosus, and there is emerg-
ing evidence for a role for TWEAK/Fn14 in compromising the
BBB in lupus (4). Also relevant to lupus is the pathogenic role
of TWEAK/Fn14 in the renal manifestation of lupus nephritis.
Indeed, evidence supporting TWEAK/Fn14-mediated pathologi-
cal mechanisms in contexts of acute kidney injury and chronic
kidney diseases is substantial and clinical targeting of TWEAK is
ongoing in lupus nephritis (5). Also addressed in this Research
Topic is the role of TWEAK/Fn14 in the pathological remodeling
underlying other inflammatory diseases, namely cardiovascular
diseases and obesity-associated Type-2 diabetes (6, 7), as well as
in myocardial remodeling leading to heart failure (8), and a com-
mon theme also addressed in these articles is the potential use of
soluble TWEAK as a biomarker for cardiovascular diseases. The
expression of soluble TWEAK in biological fluids of patients with
autoimmune/chronic inflammatory diseases and its potential as
a biomarker of these diseases is also more broadly discussed (9).
Given that TWEAK has emerged as a major cytokine regulating
skeletal muscle biology, two articles are dedicated to its role in
muscle wasting and mitochondrial dysfunction, and its complex
regulation of myogenesis where distinct roles for canonical ver-
sus non-canonical NFκB signaling have been delineated (10, 11).
Besides Fn14 upregulation in contexts of injury/disease, it is also
highly expressed on tumor cells relative to normal tissue mak-
ing it an attractive therapeutic target. Purcell et al. (12) review
the growth inhibitory activity of an Fn14-specific antibody on an
array of human tumor cells, differentially dependent on canonical
and/or non-canonical NFκB, an approach that is currently being
pursued as a novel cancer treatment.
In summary, there is substantial evidence implicating
TWEAK/Fn14 in the regulation of physiological and pathophys-
iological tissue responses, though there is still an incomplete
understanding of the role of TWEAK/Fn14-induced canonical ver-
sus non-canonical NFκB in these various contexts. Since soluble
TWEAK and membrane TWEAK differ in their capacity to induce
canonical NFκB, distinct biological responses may reflect spatial
and temporal differences in sources of TWEAK (13). New studies
continue to inform the understanding of TWEAK-induced signal-
ing, including ubiquitination events that are key to orchestrating
canonical and non-canonical NFκB activation (14).
The role of other TNF/TNFR superfamily members in shaping
tissue responses in health and disease is also reviewed, concentrat-
ing on those that can activate non-canonical NFκB. In a review on
TNFα signaling through TNFR2, Faustman and Davis (15) dis-
cuss the concept of leveraging TNFR2 agonism to reshape the T
cell compartment in autoimmune disease, and to promote tissue
regenerative processes. On the other hand, Gardam and Brink (16)
review the importance of BAFF/BAFFR-mediated non-canonical
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NFκB signaling in peripheral B cell survival and maturation. Like-
wise, CD40L–CD40-mediated activation of non-canonical NFκB
appears to be critical for B cell survival and possibly contributes to
development of B cell malignancies (17). Both BAFFR and CD40-
mediated non-canonical NFκB activation in B cells is restrained by
the adaptor protein TRAF3, and the relationship between TRAF3
degradation and non-canonical NF-kB2 activation is delineated in
an original research article (18). Beyond T and B cell activation,
positioning cues are critical for proper immune system develop-
ment and function. In this regard, LTβR plays a critical role in
lymph node development and remodeling through its delivery
of differentiation signals for reticular networks and vasculature
(19). Tissue remodeling in the context of chronic liver diseases
also features a prominent role for both LTβ and TWEAK in the
crosstalk between liver progenitor cells and hepatic stellate cells,
which can evolve into pathological fibrosis and hepatocellular
carcinoma (20). Finally, Walsh and Choi (21) review the RANKL–
RANK–OPG system, a preeminent player in the bone homeostasis,
pathologies including mammary gland tumorigenesis, and in the
interplay between bone and the immune system. This collection
of expert reviews provides a current perspective of the role of this
particular subset of TNF/TNFR family members that can acti-
vate non-canonical NFκB signaling in shaping tissue responses in
contexts of development, homeostasis, and remodeling.
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